| Alan F. List |
Alan F. List is currently the Chairman at Tampa Hillsborough Economic Development Corp. He is also the Director at TuHURA Biosciences, Inc. and the Director at Helio Health Inc. Additionally, he holds the position of Chief Medical Officer at Precision BioSciences, Inc. Dr. List is a Professor at the University of South Florida and a Member of the American Society of Clinical Oncology, Inc., the American Association for Cancer Research, and the American Society of Hematology. Previously, he served as the President & Chief Executive Officer at H. Lee Moffitt Cancer Center & Research Institute, Inc. from 2012 to 2019. He was also the Director at the National Comprehensive Cancer Network, Inc. and The MDS Foundation. Dr. List worked as a Professor at the University of Arizona and served as the President of the Society of Hematologic Oncology. He obtained his doctorate degree from the University of Pennsylvania in 1980 and completed his undergraduate and graduate degrees at Bucknell University. |
| Sinu Bhandaru |
Sinu Bhandaru is currently the Director at NC Life Sciences Organization and the Vice President-Operations & Information Technology at Precision BioSciences, Inc. Sinu previously worked as the Director-IT Operations at Novartis Vaccines & Diagnostics, Inc. (North Carolina) from 2012 to 2016. Sinu holds a graduate degree from Tulane University (Louisiana). |
| Cindy Atwell |
Cindy Atwell is currently the Chief Business Officer at Precision BioSciences, Inc. She started this position in 2022. Prior to her current role, she obtained an undergraduate degree from The Pennsylvania State University. She also holds an MBA from the Rady School of Management at UC San Diego. |
| Jeff Smith |
Jeff Smith is the founder and currently serves as the Chief Research Officer at Precision BioSciences, Inc., a company he founded in 2006. Prior to founding Precision BioSciences, Inc., Dr. Smith worked as a Scientist at Duke University Medical Center from 2000 to 2006. Dr. Smith holds a doctorate degree from The Johns Hopkins University, which he obtained in 2000, and an undergraduate degree from Franklin & Marshall College, which he obtained in 1995. |
| John Alexander Kelly |
John Alexander Kelly is currently the Director at California Biomedical Innovation Alliance since 2016 and the Chief Financial & Accounting Officer at Precision BioSciences, Inc. since 2020. Previously, he held positions such as Director-Investor Relations at Pharmacia & Upjohn, Inc., Executive Director-Investor Relations at Novartis Corp., Senior Director-Investor Relations at Pharmacia Corp., Director at HealthCare Institute of New Jersey, Treasurer & Director at California Life Sciences Association, Vice President-Investor Relations at Bausch & Lomb, Inc., Chief Communications Officer & Senior VP-IR at Forest Laboratories, Inc., Senior Vice President-Investor Relations at Merck & Co., Inc., Vice President-Investor Relations at Schering-Plough Corp., and Pharmaceutical Sales Representative at The Upjohn Co. He also served as the Chief Integration Officer & Senior Vice President at Actavis, Inc. from 2014 to 2015 and as the Chief Communications Officer & Executive VP at Allergan Ltd. (Ireland) from 2014 to 2020. Additionally, he was the President of Allergan Foundation. Mr. Kelly completed his undergraduate degree at Purdue University. |
| Kevin J. Buehler |
Kevin J. Buehler is currently the Chairman at Precision BioSciences, Inc. and the Director at Praetorian Security, Inc. He is also a Director at Read Fort Worth and a Trustee at Carroll University, Inc. In his former positions, Mr. Buehler served as a Director at Acelity LP, Inc., WaveLight AG, Advanced Medical Technology Association, KCI Holdings, Inc., United Way of Tarrant County, and Gillette Co. He was also the Division Head-Alcon at Alcon AG from 2011 to 2014 and a Member-Executive Board at Novartis AG from 2013 to 2014. Prior to that, he held the position of Division Head at Alcon Laboratories, Inc. from 1984 to 2014 and was a Principal at Snyder Drug Stores, Inc.Mr. Buehler obtained his undergraduate degree from Carroll University, Inc. |
| Juli Blanche |
Juli Blanche is currently the Chief People Officer at Precision BioSciences, Inc. She obtained an undergraduate degree from Marist College. |
| Michael Amoroso |
Michael Amoroso is currently the President, Chief Executive Officer & Director at Precision BioSciences, Inc. He is also the Chairman at Abeona Therapeutics, Inc. Previously, he worked as the SVP & Head-Cell Therapy Worldwide Commercial at Kite Pharma, Inc. Michael's education includes an undergraduate degree from Rider University and an MBA from The Leonard N Stern School of Business. |
| Samuel C. Wadsworth |
Samuel C. Wadsworth is currently an Independent Director at Precision BioSciences, Inc. since 2021 and the Chief Scientific Officer at Ultragenyx Pharmaceutical, Inc. since 2017. Previously, he worked as the Director-Molecular Biology at Genzyme Corp. from 2010 to 2013 and as the Chief Scientific Officer at Dimension Therapeutics, Inc. from 2013 to 2017. He also held a position at Sanofi-Aventis U.S. LLC. Dr. Wadsworth holds a doctorate degree from The University of Chicago and an undergraduate degree from Southern Illinois University. |
| Melinda Brown |
Melinda Brown is currently the Chairman at The University of Connecticut Foundation, Inc. She is also an Independent Director at Precision BioSciences, Inc., a Member of The American Institute of Certified Public Accountants, a Member of The Connecticut Society of Certified Public Accountants, and the Chief Financial Officer at The Draft Network. Previously, Ms. Brown worked as the Senior VP-Global Financial Shared Services at PepsiCo, Inc. She also served as the Chief Accounting Officer, Senior VP & Controller at Tapestry, Inc. from 2012 to 2019. Ms. Brown obtained her undergraduate degree and an MBA from the University of Connecticut. |
| Geno J. Germano |
Geno J. Germano is currently the President, Chief Executive Officer & Director at Elucida Oncology, Inc., Chairman at SAGE Therapeutics, Inc., Independent Director at Precision BioSciences, Inc., and a Member of the Group of 50. He previously held positions as a Director at The Medicines Co., Director at Biotechnology Innovation Organization, Director at Zoetis, Inc., Managing Director at Wyeth Australia Pty Ltd. and Wyeth New Zealand, Independent Director at Bioverativ, Inc., President & General Manager-Specialty Care at Wyeth LLC, Group President-Global Innovative Pharma Business at Pfizer Inc., President at Precigen, Inc., and Trustee at Albany College of Pharmacy & Health Sciences. Mr. Germano obtained his undergraduate degree from Albany College of Pharmacy & Health Sciences in 1983. |
| Stanley R. Frankel |
Stanley R. Frankel is currently an Independent Non-Executive Director at Precision BioSciences, Inc., an Independent Director at Myeloid Therapeutics, Inc., and the Chief Medical Officer at Cytovia Therapeutics, Inc. Previously, he worked as the SVP-Global Drug Development & Cellular Therapy at Bristol Myers Squibb Co. from 2019 to 2020, and as the VP, Head-Clinical R&D, Immuno-Oncology at Celgene Corp. from 2015 to 2019. He holds a doctorate degree from Northwestern University and an undergraduate degree from Harvard College. |
| Shari Lisa Piré |
Shari Lisa Piré is currently an Independent Director at Precision BioSciences, Inc. and the Chief Legal & Sustainability Officer at Plume Design, Inc. Previously, she served as a Director at Cobra Biologics Ltd. from 2020 to 2021 and as the Chief Legal Officer at Cognate BioServices, Inc. from 2015 to 2021. Ms. Piré obtained her undergraduate degree from the University of California, Irvine and her graduate degree from New York Law School. |
